Roche's Tecentriq Gets Priority Review For Breast Cancer
Zacks Investment Research | Nov 13, 2018 08:27PM ET
Roche Holdings AG (OTC:RHHBY) announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for the label expansion of immuno-oncology drug Tecentriq.
The agency also granted Priority Review to Tecentriq plus chemotherapy (Abraxane) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.
The FDA is expected to make a decision on approval by Mar 12, 2019.
The sBLA is based on positive data from the phase III study, Impassion 130.
We note that Roche currently has seven ongoing phase III studies investigating Tecentriq in TNBC, including early and advanced stages of the disease. Assuming approval, this Tecentriq combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic TNBC.
We remind investors that Tecentriq is already approved in the European Union, the United States and more than 80 countries for people with previously treated metastatic NSCLC and for certain types of untreated or previously treated metastatic urothelial carcinoma (mUC).
A label expansion of the drug will further boost sales.
Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space with strong demand for its HER2 franchise drugs. The HER2 franchise includes Herceptin, Perjeta and Kadcyla. Growth in Herceptin is being driven by increasing demand in both the United States and Europe due to longer treatment duration. Moreover, the subcutaneous (SC) formulation of Herceptin is being increasingly adopted. The FDA approved Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen) for adjuvant (after surgery) treatment of HER2-positive early breast cancer (EBC) at high risk of recurrence.
Shares of Roche have gained 1.6% so far this year, against the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.